Nonsurgical treatment of hemifacial microsomia by therapeutic ultrasound and hybrid functional appliance
Tarek El-Bialy1, Ali Hasan2, Ahmad Janadas3, Tarik Albaghdadi4
1Division of Orthodontics, Department of Dentistry, University of Alberta, Edmonton, Alberta, Canada; 2Division of Orthodontics, Department of Preventive Dental Sciences, Faculty of Dentistry; 3Division of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry; 4Division of Radiology, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia
Aim: Conventional treatment of patients with hemifacial microsomia involves orthognathic surgery and/or distraction osteogenesis of the mandible. Previous reports showed that low-intensity pulsed ultrasound (LIPUS) enhances mandibular growth in growing rabbits and monkeys. In monkeys, LIPUS enhanced mandibular growth when combined with functional jaw orthopedic appliances. The purpose of this pilot study was to investigate if LIPUS could enhance mandibular growth in children with hemifacial microsomia.
Methods: Five children (age range 3–11 years) with hemifacial microsomia were treated with hybrid jaw orthopedic functional appliances and treatment of the affected mandibular condyle by LIPUS for 20 minutes per day.
Results: The results showed that after one year of treatment, significant improvement of the underdeveloped side of patients’ faces and mandibles was recognized both clinically and radiographically.
Discussion: Although improvement took a longer time than did a surgical approach, optimizing this technique may achieve better results in a shorter treatment time. A randomized controlled clinical trial to investigate the effect of optimized LIPUS application or functional appliances in the treatment of hemifacial microsomia is warranted.
Keywords: hemifacial microsomia, LIPUS, non-surgical treatment, children
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H
Published Date: 23 July 2015
Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics
Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, O’Mahony B, Cassar J
Published Date: 15 June 2015
George LA, Camire RM
Published Date: 24 April 2015
Duffey H, Firszt R
Published Date: 16 April 2015
Published Date: 12 December 2014
Published Date: 22 July 2014
Published Date: 16 May 2013
Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation
Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K
Published Date: 5 December 2012
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
Published Date: 27 July 2012